{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T17:29:33Z","timestamp":1771608573297,"version":"3.50.1"},"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>The safety of antirheumatic drugs in pregnancy and their impact on maternal and neonatal outcomes are understudied. Despite pregnant individuals being excluded from clinical trials, their continued use of medications raises the importance of addressing knowledge gaps regarding safety and impact on outcomes. A scoping review was conducted following JBI methodology and PRISMA reporting guidelines to describe how antirheumatic drugs and associated adverse pregnancy outcomes have been investigated in observational studies using claims data. Electronic databases (MEDLINE (Ovid), Embase (Ovid), and CINAHL (EBSCO)) and grey literature were searched for observational studies using claims data to evaluate antirheumatic drug effects on pregnancy outcomes in individuals with rheumatic diseases. Of 4,325 articles identified, 38 eligible articles were included. The effects of conventional synthetic disease-modifying antirheumatic drugs (n =\u2009 37, 97.4%) and tumor necrosis factor inhibitor biological agents (n =\u2009 23, 60.5%) were extensively reported. Preterm birth (n =\u2009 25, 65.8%), preeclampsia (n =\u2009 17, 44.7%), stillbirth (n =\u2009 17, 44.7%), caesarean delivery (n =\u2009 16, 42.1%), and congenital anomalies (n =\u2009 14, 36.8%) were the most reported adverse pregnancy outcomes. Of 14 studies reporting congenital anomalies, 12 (85.7%) specified ICD codes and 4 (28.6%) specified validated definitions for identification in claims data, the most of any reported adverse pregnancy outcome. We found considerable ambiguity and heterogeneity in adverse pregnancy outcome definitions in claims data. There is a need for greater transparency and consistency in outcome reporting in observational studies using claims data.<\/jats:p>\n<jats:p><jats:bold>Protocol registration details:<\/jats:bold> OSF, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/osf.io\/5e6tp\" xlink:type=\"simple\">https:\/\/osf.io\/5e6tp<\/jats:ext-link><\/jats:p>","DOI":"10.1371\/journal.pone.0319703","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T19:25:38Z","timestamp":1743449138000},"page":"e0319703","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Use of healthcare administrative claims data in observational studies of antirheumatic drug effects on pregnancy outcomes: A scoping review"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6264-1466","authenticated-orcid":true,"given":"Shenthuraan","family":"Tharmarajah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Araniy","family":"Santhireswaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8774-2335","authenticated-orcid":true,"given":"Yasmeen","family":"Ameeriar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa M.","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dharini","family":"Mahendira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard","family":"Berger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mina","family":"Tadrous","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara J. T.","family":"Guilcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,3,31]]},"reference":[{"issue":"2","key":"pone.0319703.ref001","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.3346\/jkms.2022.37.e18","article-title":"Risk of pregnancy complications and low birth weight offsprings in Korean women with rheumatic diseases: A nationwide population-based study","volume":"37","author":"JS Park","year":"2022","journal-title":"J Korean Med Sci"},{"issue":"12","key":"pone.0319703.ref002","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1177\/0961203319877258","article-title":"Pregnancy outcomes in women with rheumatic diseases: A real-world observational study in Japan","volume":"28","author":"E Sugawara","year":"2019","journal-title":"Lupus"},{"issue":"3S","key":"pone.0319703.ref003","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/j.semarthrit.2019.09.010","article-title":"Current perspectives on fertility, pregnancy and childbirth in patients with Rheumatoid Arthritis","volume":"49","author":"HTW Smeele","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"pone.0319703.ref004","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.3899\/jrheum.140583","article-title":"Disease severity and pregnancy outcomes in women with rheumatoid arthritis: Results from the organization of teratology information specialists autoimmune diseases in pregnancy project","volume":"42","author":"B Bharti","year":"2015","journal-title":"J Rheumatol"},{"issue":"8","key":"pone.0319703.ref005","first-page":"699","article-title":"State of the art: Fertility and pregnancy in rheumatic diseases","volume":"80","author":"I Haase","year":"2021","journal-title":"Z Rheumatol"},{"issue":"6\u20137","key":"pone.0319703.ref006","doi-asserted-by":"crossref","first-page":"A520","DOI":"10.1016\/j.autrev.2011.12.002","article-title":"Fetal outcome in autoimmune diseases","volume":"11","author":"G Carvalheiras","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"4","key":"pone.0319703.ref007","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/art.41191","article-title":"2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases","volume":"72","author":"LR Sammaritano","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"pone.0319703.ref008","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1093\/rheumatology\/keac551","article-title":"British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: Immunomodulatory anti-rheumatic drugs and corticosteroids","volume":"62","author":"MD Russell","year":"2023","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"pone.0319703.ref009","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","article-title":"The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation","volume":"75","author":"C G\u00f6testam Skorpen","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"pone.0319703.ref010","doi-asserted-by":"crossref","first-page":"e000166","DOI":"10.1136\/rmdopen-2015-000166","article-title":"Prevalence of rheumatic and musculoskeletal diseases and their impact on health-related quality of life, physical function and mental health in Portugal: Results from EpiReumaPt- a national health survey","volume":"2","author":"JC Branco","year":"2016","journal-title":"RMD Open"},{"issue":"1","key":"pone.0319703.ref011","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/bcp.14914","article-title":"Ethical issues in therapeutic use and research in pregnant and breastfeeding women","volume":"88","author":"ED Weld","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"pone.0319703.ref012","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/s12913-016-1562-8","article-title":"Is real world evidence influencing practice? A systematic review of CPRD research in NICE guidances","volume":"16","author":"JO Oyinlola","year":"2016","journal-title":"BMC Health Serv Res"},{"issue":"7","key":"pone.0319703.ref013","first-page":"1317","article-title":"Harnessing the power of administrative data linkage: Results from the Ontario best practices research initiative clinical linked cohort","volume":"42","author":"M Tatangelo","year":"July 2015","journal-title":"J Rheumatol"},{"issue":"8","key":"pone.0319703.ref014","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1093\/rheumatology\/keaa064","article-title":"Maternal and neonatal outcomes associated with biologic exposure before and during pregnancy in women with inflammatory systemic diseases: A systematic review and meta-analysis of observational studies","volume":"59","author":"NW Tsao","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"pone.0319703.ref015","doi-asserted-by":"crossref","first-page":"e001512","DOI":"10.1136\/rmdopen-2020-001512","article-title":"Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: A systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis","volume":"7","author":"NMT Roodenrijs","year":"2021","journal-title":"RMD Open"},{"issue":"5","key":"pone.0319703.ref016","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1097\/AOG.0000000000003755","article-title":"Rheumatologic medication use during pregnancy","volume":"135","author":"EA Peterson","year":"2020","journal-title":"Obstet Gynecol"},{"issue":"11","key":"pone.0319703.ref017","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1007\/s10067-019-04699-8","article-title":"A comprehensive review of rituximab therapy in rheumatoid arthritis patients","volume":"38","author":"S Tavakolpour","year":"2019","journal-title":"Clin Rheumatol"},{"issue":"10","key":"pone.0319703.ref018","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.11124\/JBIES-20-00167","article-title":"Updated methodological guidance for the conduct of scoping reviews","volume":"18","author":"MDJ Peters","year":"2020","journal-title":"JBI Evid Synth"},{"issue":"7","key":"pone.0319703.ref019","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation","volume":"169","author":"AC Tricco","year":"2018","journal-title":"Ann Intern Med"},{"issue":"1","key":"pone.0319703.ref020","doi-asserted-by":"crossref","first-page":"106","DOI":"10.11124\/JBIES-23-00039","article-title":"Use of administrative claims data in observational studies of antirheumatic medication effects on pregnancy outcomes: A scoping review protocol","volume":"22","author":"S Tharmarajah","year":"2024","journal-title":"JBI Evid Synth"},{"key":"pone.0319703.ref021","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"MJ Page","year":"2021","journal-title":"BMJ"},{"issue":"6","key":"pone.0319703.ref022","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"JS Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"pone.0319703.ref023","first-page":"CD010227","article-title":"Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis","author":"GS Hazlewood","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"pone.0319703.ref024","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1093\/rheumatology\/keu394","article-title":"High-risk pregnancy and the rheumatologist","volume":"54","author":"MC Soh","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"pone.0319703.ref025","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3109\/03009742.2011.626442","article-title":"Outcomes after anti-rheumatic drug use before and during pregnancy: A cohort study among 150,000 pregnant women and expectant fathers","volume":"41","author":"KK Viktil","year":"2012","journal-title":"Scand J Rheumatol"},{"issue":"1","key":"pone.0319703.ref026","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s10995-017-2358-0","article-title":"Making decisions about medication use during pregnancy: Implications for communication strategies","volume":"22","author":"MM Lynch","year":"2017","journal-title":"Matern Child Health J"},{"issue":"8","key":"pone.0319703.ref027","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/ecco-jcc\/jjw052","article-title":"Perceptions and attitudes towards medication adherence during pregnancy in inflammatory bowel disease","volume":"10","author":"ZR Gallinger","year":"2016","journal-title":"J Crohns Colitis"},{"issue":"1","key":"pone.0319703.ref028","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.schres.2014.07.034","article-title":"Discontinuation of antipsychotic medication in pregnancy: A cohort study","volume":"159","author":"I Petersen","year":"2014","journal-title":"Schizophr Res"},{"issue":"2","key":"pone.0319703.ref029","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.cgh.2015.08.039","article-title":"Low risk of birth defects for infants whose mothers are treated with anti-tumor necrosis factor agents during pregnancy","volume":"14","author":"G Br\u00f6ms","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"pone.0319703.ref030","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.reprotox.2013.11.004","article-title":"Pregnancy outcome following gestational exposure to TNF-alpha-inhibitors: A prospective, comparative, observational study","volume":"43","author":"O Diav-Citrin","year":"2014","journal-title":"Reprod Toxicol"},{"key":"pone.0319703.ref031","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1016\/j.ejogrb.2018.08.528","article-title":"Lack of placental transfer of certolizumab pegol during pregnancy: Results from CRIB, a prospective, postmarketing, multicenter, pharmacokinetic study","volume":"234","author":"X Mariette","year":"2019","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"11","key":"pone.0319703.ref032","doi-asserted-by":"crossref","first-page":"937","DOI":"10.5498\/wjp.v11.i11.937","article-title":"Therapeutic termination of pregnancy and women\u2019s mental health: Determinants and consequences","volume":"11","author":"E di Giacomo","year":"2021","journal-title":"World J Psychiatry"},{"issue":"3","key":"pone.0319703.ref033","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1007\/s10995-011-0797-6","article-title":"Incidence of severe adverse neonatal outcomes: Use of a composite indicator in a population cohort","volume":"16","author":"SJ Lain","year":"2012","journal-title":"Matern Child Health J"},{"issue":"8","key":"pone.0319703.ref034","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/pds.3446","article-title":"Validity of congenital malformation diagnostic codes recorded in Qu\u00e9bec\u2019s administrative databases","volume":"22","author":"L Blais","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"pone.0319703.ref035","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/pds.4967","article-title":"Validation of algorithms to identify adverse perinatal outcomes in the Medicaid Analytic Extract database","volume":"29","author":"M He","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"pone.0319703.ref036","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/pds.4295","article-title":"Reporting to improve reproducibility and facilitate validity assessment for healthcare database studies V1.0","volume":"26","author":"SV Wang","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"pone.0319703.ref037","doi-asserted-by":"crossref","first-page":"k3532","DOI":"10.1136\/bmj.k3532","article-title":"The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE)","volume":"363","author":"SM Langan","year":"2018","journal-title":"BMJ"},{"issue":"10","key":"pone.0319703.ref038","doi-asserted-by":"crossref","first-page":"e1001885","DOI":"10.1371\/journal.pmed.1001885","article-title":"The reporting of studies conducted using observational routinely-collected health data (RECORD) statement","volume":"12","author":"EI Benchimol","year":"2015","journal-title":"PLoS Med"},{"issue":"7624","key":"pone.0319703.ref039","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies","volume":"335","author":"E von Elm","year":"2007","journal-title":"BMJ"},{"issue":"10","key":"pone.0319703.ref040","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1371\/journal.pmed.0040297","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE): Explanation and elaboration","volume":"4","author":"JP Vandenbroucke","year":"2007","journal-title":"PLoS Med"},{"issue":"2","key":"pone.0319703.ref041","first-page":"1135","article-title":"ICES: Data, discovery, better health","volume":"4","author":"MJ Schull","year":"2020","journal-title":"Int J Popul Data Sci"},{"issue":"4","key":"pone.0319703.ref042","doi-asserted-by":"crossref","first-page":"e0284893","DOI":"10.1371\/journal.pone.0284893","article-title":"Identification of pregnancies and their outcomes in healthcare claims data, 20082019: An algorithm","volume":"18","author":"EC Ailes","year":"2023","journal-title":"PLoS One"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0319703","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T19:27:07Z","timestamp":1743449227000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0319703"}},"subtitle":[],"editor":[{"given":"Keiko","family":"Hosohata","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,3,31]]},"references-count":42,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0319703","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,31]]}}}